Brachytherapy Prostate Cancer Survival Rates
A full 14.29% or 1 out of every 7 men will be diagnosed with prostate cancer in his lifetime. One out of every three men who die from cancer had been diagnosed with prostate cancer. While prostate surgery, or prostatectomy, has proven effective in healing the cancer, there’s a 10% chance of urinary incontinence and a 50% chance of sexual dysfunction after the procedure.
What is Brachytherapy?
Cancer is normally treated with radiation, through a beam of radiation directed at the affected areas to kill cancer cells. Brachytherapy, to put it simply, does the radiation treatment from the inside out. It can also be called “internal radiation.” Small sources of radiation, called “seeds,” are placed in or near the affected area, for more targeted radiation treatment.
What are brachytherapy prostate cancer survival rates?
The Prostate Cancer Foundation of Chicago did a study over 11 years, from 1997 to 2008. They studied over 9,000 patients with prostate cancer. Of the patients, 67.5% were considered low risk, 29.36% were considered medium-risk or intermediate, and 1.01% were considered high-risk patients.
All of the patients were treated with brachytherapy, wherein an ultrasound probe located the affected area and radiation seeds were injected into the prostate. Of the patients, those considered low-risk had a 95% 5-year survival rate. Medium-risk patients had an 89% 5-year survival rate, and high-risk patients had a 71% 5-year survival rate.
To survive 1 to 3 years is considered healthy. Overall, prostatectomy 5-year survival rates range from 55% to 71%. While it is possible for lower-risk patients to survive up to 5 years without brachytherapy, only 29% of high-risk prostate cancer patients survive 5 years. Comparatively, brachytherapy for prostate cancer has excellent survival raters.